National Cancer Institute - NCI Division of Cancer Treatment and ...

More documents

Recommendations

Info

In Vivo Cellular and Molecular Imaging Center Institutions and Principal Investigators Johns Hopkins University Dr. Zaver Bhujwalla Massachusetts General Hospital Dr. Ralph Weissleder Memorial Sloan-Kettering Cancer Center Dr. Ron Blasberg Stanford University Dr. Sanjiv (Sam) Gambhir types of tumor cells at different disease stages. CIP anticipates a recompetition in fiscal year 2007 for five of the 10 SAIRPs. As a result of this recompetition, CIP expects to fund eight five-year SAIRPs using the U24 cooperative agreement mechanism, bringing the total number of NCI-funded SAIRPs to 13. In Vivo Cellular and Molecular Imaging Centers http://imaging.cancer.gov/ programsandresources/ specializedinitiatives/icmics Contact: Anne E. Menkens, Ph.D. 301-435-9024, am187k@nih.gov In Vivo Cellular and Molecular Imaging Center (ICMIC) grants bring together interdisciplinary scientific teams to lead cutting-edge cancer molecular imaging research in P50 center grants that last University of California, Los Angeles Dr. Harvey Herschman University of Michigan Dr. Brian Ross University of Missouri-Columbia Dr. Wynn Volkert Washington University in St. Louis Dr. David Piwnica-Worms five years. The initiative focuses on human disease and exclusively supports translational research. ICMICs provide unique core facilities to support oncology imaging research, flexibility to respond to exciting pilot research opportunities, and interdisciplinary career development opportunities for the young investigators who will be tomorrow’s innovators. The program promotes coordination, interrelationships, and scientific synergy among research components and resources, leading to highly integrated imaging centers. CIP is currently supporting eight ICMICs pursuant to a program announcement (http://grants1.nih.gov/grants/guide/ pa-files/PAR-04-069.html) that closed last year. However, CIP reissued a program announcement for ICMIC applications in spring 2006. C A N C E R I M A G I N G P R O G R A M ■ 53
C U R R E N T F U N D I N G O P P O R T U N I T I E S Clinical Cancer Therapy and Prevention Research Program Announcement: PA-04-046: http://grants.nih.gov/grants/ guide/pa-files/PA-04-046.html (expiration date extended to 11/2/2006) Contacts: Keyvan Farahani, Ph.D.—imaging 301-451-2651, farahank@mail.nih.gov Roy Wu, Ph.D.—clinical grants & contracts 301-496-8866, wur@ctep.nci.nih.gov CIP supports translational clinical studies and encourages investigators to conduct trials that will move discoveries and advances in basic biology and drug development to the patient’s bedside. This initiative, which supports R01 grants to individual investigators for up to five years, encompasses a full range of therapeutic and preventive studies that employ single therapies as well as combinations that can include conventional (drugs, radiation, surgery) or unconventional (dietary supplements, bioactive food components, hypothermia, and hyperthermia) elements. This initiative also supports programs in molecular profiling, as well as correlative studies that have been linked to therapeutic and preventive trials. 54 ■ P R O G R A M A C C O M P L I S H M E N T S 2 0 0 6 In Vivo Cancer Imaging Exploratory/ Developmental Grants Program Announcement: PA-04-045: http://grants.nih.gov/grants/ guide/pa-files/PA-04-045.html (expiration date extended to 11/2/2006) Contact: Anne E. Menkens, Ph.D. 301-435-9024, am187k@nih.gov Innovative in vivo cancer imaging applications have an expanding potential to improve the detection and diagnosis of cancer and alter the clinical management of cancer patients. This CIP initiative provides investigators at all career levels with a level of funding adequate for the initial feasibility testing of high-risk/high-impact cancer imaging concepts and generation of experimental preliminary data. Investigators from other scientific disciplines who wish to apply and integrate new imaging reagents and technologies in unique ways are also eligible for this R21 exploratory/developmental grant program, which provides nonrenewable funding for up to two years. This CIP program has been available to investigators since 1999 and was recently approved for an additional three-year reissuance. Each release of this continuing series of announcements has responded to changes in the field of imaging. In the newest announcement, additional emphasis is placed on the development and application of imaging agents and methodologies to monitor response to therapy. The CIP projects funded through this mechanism have precedent-setting potential in new areas of in vivo cancer imaging.
Page 1 and 2:
National Cancer Institute U.S. DEPA
Page 3 and 4:
ii ■ P R O G R A M A C C O M P L
Page 5 and 6:
Clinical trials performed using an
Page 7 and 8: Dr. James H. Doroshow, Director Jam
Page 9 and 10: Cancer Diagnosis Program Dr. Sheila
Page 11 and 12: DCTD Research Grants 6 ■ P R O G
Page 13 and 14: disease-specific steering committee
Page 15 and 16: ■ The DCTD Developmental Therapeu
Page 17 and 18: P A R T N E R S H I P S A N D C O L
Page 19 and 20: laboratories. Dr. Kevin Dobbin, BRB
Page 21 and 22: ■ Gene expression patterns and pr
Page 23 and 24: Simon R. DNA microarrays for diagno
Page 25 and 26: Microarray Myths and Truths Myths
Page 27 and 28: target, is sensitive to the agent.
Page 29 and 30: O T H E R B I O S T A T I S T I C A
Page 31 and 32: almost inevitably leads to an invas
Page 33 and 34: Software and Technical Report Archi
Page 35 and 36: Biomarker Development Process Marke
Page 37 and 38: Strategic Partnering to Evaluate Ca
Page 39 and 40: C U R R E N T F U N D I N G O P P O
Page 41 and 42: P A R T N E R S H I P S A N D C O L
Page 43 and 44: several types of cancer TMAs have b
Page 45 and 46: Courtesy of NCI Visuals Online, Bil
Page 47 and 48: ■ Cooperative Human Tissue Networ
Page 49 and 50: Progress in many areas of cancer re
Page 51 and 52: Diagnostic Imaging Program in 1996,
Page 53 and 54: NCI Visuals Online, Terese Winslow,
Page 55 and 56: ■ Support development and deliver
Page 57: Small Animal Imaging Resource Progr
Page 61 and 62: Quick-Trials for Imaging and Image-
Page 63 and 64: Association of American Cancer Inst
Page 65 and 66: Food and Drug Administration and Ce
Page 67 and 68: Dr. Edward A. Neuwelt, Oregon Healt
Page 69 and 70: Virtual Colonoscopy Training Collec
Page 71 and 72: Not only does CTEP identify promisi
Page 73 and 74: The Clinical Trials Cooperative Gro
Page 75 and 76: of pediatric cancers and therapeuti
Page 77 and 78: the front line treatment of chronic
Page 79 and 80: Quick-Trials for Novel Cancer Thera
Page 81 and 82: Industry Collaborators Agent Name 7
Page 83 and 84: Industry Collaborators Agent Name 7
Page 85 and 86: NCI Visuals Online, George McGregor
Page 87 and 88: provided for use in this clinical t
Page 89 and 90: with or without bevacizumab (NSC #
Page 91 and 92: Oxaliplatin-Based Regimen Permits S
Page 93 and 94: egular checkups to look for lymph-n
Page 95 and 96: NCI Visuals Online. Human lymphoma
Page 97 and 98: T O O L S , P R O D U C T S , A N D
Page 99 and 100: ■ Clinical Trials Monitoring Bran
Page 101 and 102: DTP’s staff and administered gran
Page 103 and 104: therapeutics. Proposed exploratory
Page 105 and 106: M A J O R O N G O I N G I N I T I A
Page 107 and 108: National Cancer Institute. discover
Page 109 and 110:
C U R R E N T F U N D I N G O P P O
Page 111 and 112:
DTP oversees animal-production faci
Page 113 and 114:
disease can require considerable in
Page 115 and 116:
National Cancer Institute. commerci
Page 117 and 118:
The Type 1 Diabetes Rapid Access to
Page 119 and 120:
H I S T O R Y - M A R K I N G E V E
Page 121 and 122:
With this approach, patients are no
Page 123 and 124:
This included a camptothecin deriva
Page 125 and 126:
RRP supports research involving a v
Page 127 and 128:
Laredo Medical Center, Laredo, TX h
Page 129 and 130:
With TELESYNERGY® as a link, healt
Page 131 and 132:
Radiation Bioterrorism Research and
Page 133 and 134:
Enhanced Radiosensitivity The Molec
Page 135 and 136:
M E E T I N G S A N D W O R K S H O
Page 137 and 138:
Cancer Imaging Program 132 ■ P R
Page 139 and 140:
Cancer Therapy Evaluation Program,
Page 141 and 142:
Developmental Therapeutics Program,
Page 143 and 144:
Developmental Therapeutics Program,
show all

National Cancer Institute - NCI Division of Cancer Treatment and ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?